VAIA
EGRX

Virtus Alternative Investment Advisers’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Virtus Alternative Investment Advisers’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-141
Closed -$7K – 242
2020
Q4 		$7K Sell
141
-137
-49% -$6.41K 0.1% 158
2020
Q3 		$12K Buy
278
+14
+5% +$612 0.22% 76
2020
Q2 		$13K Buy
+264
New +$13.2K 0.2% 220

Other funds holding EGRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Virtus Alternative Investment Advisers's EGRX Position: Q1 2021 in Review

Virtus Alternative Investment Advisers sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2021, closing a stake of 141 shares — an estimated $7K sold.

Virtus Alternative Investment Advisers first reported a position in EGRX in Q2 2020 and held it in 3 quarters. The position peaked at $13K in Q2 2020. 155 funds tracked by Wall St. Rank hold EGRX as of Q1 2021.

  • Virtus Alternative Investment Advisers reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Virtus Alternative Investment Advisers sold 141 Eagle Pharmaceuticals, Inc. shares in Q1 2021, an estimated $7K.
  • Virtus Alternative Investment Advisers first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2020 and held it in 3 quarters.
  • Virtus Alternative Investment Advisers's Eagle Pharmaceuticals, Inc. position peaked at $13K in Q2 2020.
  • 155 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2021.

Based on Virtus Alternative Investment Advisers's 13F filing for Q1 2021.